

# Elite Pharmaceuticals, Inc. Appoints Dr. Jason M. LePree as Vice President of Scientific Affairs

Release: 1/5/2021 7:00:00 AM

**NORTHVALE, NJ / ACCESSWIRE / January 5, 2021 /** Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing and manufacturing niche generic products, is pleased to announce the hiring of Dr. Jason M. LePree as Vice President of Scientific Affairs to oversee all technical facets of Elite's pharmaceutical and product development programs. Hiring Dr. LePree will bolster Elite's efforts to develop new products and to facilitate improving Elite's overall scientific capabilities.

"Jason joins Elite with a wealth of experience in formulations and analytical development and is an important addition for product development at Elite," said Nasrat Hakim. "We welcome Jason to our team."

Dr. LePree has over 20 years of pharmaceutical development experience in small, mid-sized, and large branded and generic pharmaceutical companies including scientific leadership positions at Ferring International Pharmaceutical Science Center - US, Gattefossé Corporation, Novartis, and Capsugel. Dr. LePree received his B.S. degree in Pharmacy from Rutgers University and his Doctor of Philosophy degree in Pharmacy (Pharmaceutics) with a minor in Chemistry from the University of Wisconsin-Madison. Dr. LePree has experience in Formulation Development, Materials Characterization, and Analytical Sciences.

## About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company which develops niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products which have been licensed to Lannett Company, Glenmark Pharmaceuticals, Inc., and TAGI Pharma. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance, or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties, and other factors not under the control of Elite, which may cause actual results, performance, or achievements of Elite to be materially different from the results, performance, or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA, and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.

## CONTACT:

For Elite Pharmaceuticals, Inc.  
Dianne Will, Investor Relations  
518-398-6222  
[Dianne@elitepharma.com](mailto:Dianne@elitepharma.com)  
[www.elitepharma.com](http://www.elitepharma.com)

SOURCE: Elite Pharmaceuticals, Inc.